Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Grape Seed Compound Slows Progression of Alzheimer’s Disease in Mouse Model

By BiotechDaily International staff writers
Posted on 15 May 2012
A team of neurobiologists has identified the specific polyphenolic compound responsible for improved cognitive function in a mouse model of Alzheimer's disease (AD).

Investigators at Mount Sinai School of Medicine (New York, NY, USA) had previously shown that compounds present in grape seed polyphenolic extract (GSPE) protected against the development of Alzheimer’s disease by blocking the formation of toxic amyloid-beta (A-beta) oligomers in brain tissue.

In the current study, which was published in the April 11, 2012, issue of the Journal of Neuroscience, they revealed new information relating to the bioavailability, metabolism, and bioactivity of this compound, especially in the brain.

They reported that GSPE is comprised of the proanthocyanidin (PAC) catechin and epicatechin in monomeric (Mo), oligomeric, and polymeric forms. Following oral administration of the independent GSPE forms, only Mo was able to improve cognitive function and only Mo metabolites could selectively reach and accumulate in the brain. Furthermore, they showed that a biosynthetic epicatechin metabolite, 3′-O-methyl-epicatechin-5-O-beta-glucuronide (3′-O-Me-EC-Gluc), one of the PAC metabolites identified in the brain following Mo treatment, promoted basal synaptic transmission and long-term potentiation at physiologically relevant concentrations in hippocampus slices through mechanisms associated with cAMP response element binding protein (CREB) signaling. This activity benefited cognition by improving synaptic plasticity in the brain.

“My team, along with many members of the scientific community, did not know how we could harness the efficacy of naturally occurring polyphenols in food for treatment of Alzheimer’s disease,” said senior author Dr. Giulio Maria Pasinetti, professor of neurology at Mount Sinai School of Medicine. “We were skeptical that these naturally occurring polyphenols would reach the brain because they are extensively metabolized following ingestion. While this is an exciting development, we have a lot to discover and many years of testing before this agent can be considered in humans. I look forward to further studying this compound to determine its feasibility as a treatment for Alzheimer’s disease.”

Related Links:

Mount Sinai School of Medicine




RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.